HUTCHMED· @hutchmed · X·· 20 天前AI 评分42
AI 导读
我们很高兴地宣布,美国FDA授予索乐匹尼布孤儿药资格认定,这是我们用于治疗原发性免疫性血小板减少症(ITP)的新型口服Syk抑制剂。https://www.hutch-med.com/sovleplenib-fda-orphan-drug/
正文
We are pleased to announce US FDA Orphan Drug Designation for sovleplenib, our novel oral Syk inhibitor for primary immune thrombocytopenia (ITP). https://www.hutch-med.com/sovleplenib-fda-orphan-drug/
来源:HUTCHMED · x.com